Kangya

Kangya of Ningxia Pharmaceutical Co., Ltd. (Stock Code: 872320) is a national high-tech enterprise that integrates the research, production, and sales of chemical drug preparations and active pharmaceutical ingredients. The company is located in Yinchuan High-tech Industrial Development Zone, Ningxia, covering a total area of 500 mu with nearly 300 employees. From 2017 to 2019, it received honorary titles such as "Provincial Industrial Enterprise Industry Benchmark Award," "Technology-based Small and Medium-sized Enterprise," "Specialized, Refined, Unique, and Innovative Demonstration Enterprise," "Top 100 Enterprises in Ningxia Quality," "Top 50 Small and Medium-sized Enterprises in Ningxia," "Top 100 in Maker China Innovation and Entrepreneurship Competition," "Social Insurance Integrity Unit," and "Advanced Enterprise in Production Safety." The company has a professional R&D team with independent innovation capabilities and has hired academicians, Yangtze River Scholars, and renowned professors as special technical consultants. It possesses technical platforms recognized by the state and the autonomous region, including the "National-Local Joint Engineering Laboratory," "Autonomous Region Enterprise Technology Center," "Autonomous Region Science and Technology Innovation Team," "Ningxia Hui Autonomous Region New Drug Formulation Technology Innovation Center," "Academician Expert Workstation," and "Innovation Studio." In the past three years, R&D expenditure accounted for 14% of total revenue. Currently, there is one innovative Class I drug in the preclinical evaluation stage, two innovative Class II drugs in clinical research and clinical application stages, respectively. The company has undertaken key projects from the National Development and Reform Commission, the Torch Plan Project of the Ministry of Science and Technology, SME projects of the Ministry of Science and Technology, and key R&D plans of the autonomous region. By the end of 2019, the company had obtained 27 valid invention patents, including 25 Chinese patents and one each in the United States and Europe. The company focuses on the research, production, and sales of formulations and active pharmaceutical ingredients for cardiovascular and cerebrovascular diseases, geriatric chronic diseases, and ophthalmic diseases. Its product forms include tablets, granules, capsules, eye drops, and chemical active pharmaceutical ingredients, totaling 42 approval numbers. Main products include Calcium Dobesilate Capsules and their active pharmaceutical ingredients, Meloxicam Tablets and their active pharmaceutical ingredients, Indapamide Sustained-Release Tablets, and eye drop series. Among them, Shengchang - Indapamide Sustained-Release Tablets rank second in market share in China's niche market; Hauchang - Calcium Dobesilate Capsules passed the national generic drug consistency evaluation in November 2019.